Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to 3.92%.

  • Marimed's EBIT Margin rose 6100.0% to 3.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46%, marking a year-over-year decrease of 38100.0%. This contributed to the annual value of 1.84% for FY2024, which is 78400.0% down from last year.
  • Marimed's EBIT Margin amounted to 3.92% in Q3 2025, which was up 6100.0% from 2.88% recorded in Q2 2025.
  • Marimed's 5-year EBIT Margin high stood at 36.85% for Q2 2021, and its period low was 2.97% during Q4 2024.
  • Over the past 5 years, Marimed's median EBIT Margin value was 8.48% (recorded in 2023), while the average stood at 10.68%.
  • Examining YoY changes over the last 5 years, Marimed's EBIT Margin showed a top increase of 150700bps in 2021 and a maximum decrease of -356100bps in 2021.
  • Over the past 5 years, Marimed's EBIT Margin (Quarter) stood at 3.88% in 2021, then soared by 122bps to 8.62% in 2022, then decreased by -28bps to 6.2% in 2023, then plummeted by -148bps to 2.97% in 2024, then skyrocketed by 232bps to 3.92% in 2025.
  • Its EBIT Margin was 3.92% in Q3 2025, compared to 2.88% in Q2 2025 and 2.24% in Q1 2025.